MADRID, Oct. 7 (Reuters) - Spain's Zeltia ZEL.MC on Wednesday said it had decided not to expand capital after European regulators recently recommended the loss-making pharmaceutical firm's Yondelis drug for use in the treatment of ovarian cancer.
Shortly after the regulators’ decision on Sept. 25, Zeltia’s chairman, Jose Maria Fernández Sousa-Faro, said he thought the company may need to call on shareholders to boost capital.
Zeltia has been developing Yondelis for use in combination with Johnson & Johnson's JNJ.N Doxil for the treatment of ovarian cancer. (Reporting by Martin Roberts; editing by Elaine Hardcastle)
Our Standards: The Thomson Reuters Trust Principles.